<DOC>
	<DOCNO>NCT02626715</DOCNO>
	<brief_summary>The purpose study compare safety efficacy reduced-intensity conditioning myeloablative conditioning regimen prior HSCT high-risk AML/MDS pediatric young adult patient . This study investigate use two novel condition therapy hematopoietic stem cell transplant ( HSCT ) . The primary focus investigator ' myeloablative reduced-intensity conditioning regimens reduce overall toxicity pediatric young adult patient high-risk AML/MDS significant pretransplant comorbidities would ineligible proceed HSCT previously receive potentially life-saving treatment .</brief_summary>
	<brief_title>Reduced-Intensity Conditioning ( RIC ) Myeloablative Conditioning ( MAC ) HSCT AML/MDS</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Alkylating Agents</mesh_term>
	<criteria>Eligibility Criteria Myeloablative Conditioning Transplant 1 . Patient must 1 month 22 year age . 2 . Diagnosis acute myeloid leukemia myelodysplastic syndrome , either highrisk , relapse primary refractory , minimal residual disease ( MRD ) positive without circulate myeloblast active extramedullary disease time transplant . Active marrow disease permit . ( `` Highrisk '' AML feature define follow : great 15 % blast bone marrow first course Induction chemotherapy ; adverse cytogenetic abnormality monosomy 5 , monosomy 7 , 5q deletion ; presence FLT3 positive internal tandem duplication ( FLT3/ITD+ ) , particularly high allelic ratio ; treatmentrelated AML . ) 3 . Stem cell source include bone marrow , peripheral blood stem cell , umbilical cord blood . 4 . Related bone marrow , peripheral blood stem cell , cord blood unit : Sibling human leukocyte antigen ( HLA ) match A , B , DRB1 locus . Unrelated cord blood unit minimum 4/6 match antigen level HLA A B , allele level HLA DRB1 locus . Unrelated bone marrow peripheral blood stem cell donor HLA allele level match A , B , C , DRB1 . 5 . Minimum prefreezing cell dose cord blood unit : 3 x 10^7 total nucleate cells/kg 1.5 x 10^5 CD34+ cells/kg ( cluster differentiation 34 ) . If attainable , double cord blood transplant consider . 6 . Patient , parent , legal guardian must give write informed consent and/or assent . 7 . Patient must adequate performance status ( Lansky score ≥60 % patient &lt; 16 year ; Karnofsky score ≥60 % patient ≥16 year ) . 8 . Patient must adequate pretransplant organ function define : 8a . Renal : Creatinine clearance radioisotope glomerular filtration rate ( GFR ) ≥70 mL/min/1.73 m2 . 8b . Hepatic : Total bilirubin ≤2.0 mg/dL unless increase bilirubin attributable Gilbert 's syndrome ; SGOT ( AST ) ( serum glutamate oxaloacetate transaminase ) , SGPT ( ALT ) ( serum glutamate pyruvate transaminase ) , Alkaline Phosphatase &lt; 4 x upper limit normal ( ULN ) age . 8c . Cardiac : Normal cardiac function echocardiogram radionuclide scan , defined leave ventricular ejection fraction rest &gt; 45 % , shorten fraction &gt; 26 % . 8d . Pulmonary : FEV1 ( forced expiratory volume one second ) , FVC ( force vital capacity ) , DLCO ( diffuse capacity lung carbon monoxide ) ( correct hemoglobin ) ≥50 % predict ; unable perform pulmonary function test , oxygen saturation ≥92 % room air . Eligibility Criteria ReducedIntensity Conditioning Transplant 1 . Patient must 0 22 year age . 2 . Patient must meet criterion 5.1.25.1.7 eligibility criterion . 3 . Patient exclude myeloablative conditioning transplant due failure meet criterion outline 5.1.8 . 4 . Patient must adequate pretransplant organ function define : 4a . Renal : Creatinine clearance radioisotope GFR ≥70 mL/min/1.73 m2 . 4b . Hepatic : Total bilirubin ≤2.5 mg/dL unless increase bilirubin attributable Gilbert 's syndrome ; SGOT ( AST ) , SGPT ( ALT ) , Alkaline Phosphatase &lt; 5 x upper limit normal ( ULN ) age . 4c . Cardiac : Normal cardiac function echocardiogram radionuclide scan , defined leave ventricular ejection fraction rest &gt; 40 % , shorten fraction &gt; 26 % . 4d . Pulmonary : FEV1 , FVC , DLCO ( correct hemoglobin ) ≥40 % predict ; unable perform pulmonary function test , oxygen saturation ≥92 % room air . Exclusion Criteria Myeloablative Conditioning Transplant 1 . Recipient autologous stem cell transplant . 2 . Allogeneic hematopoietic stem cell transplant within previous 3 month . 3 . Uncontrolled bacterial , viral , fungal , infection time cytoreduction . Uncontrolled infection define positive blood culture fever &gt; 38.0 within 2448 hour start condition therapy . 4 . Evidence HIV/HTLV ( human Tlymphotropic virus ) infection HIV/HTLV positive serology . 5 . Pregnancy lactate . All females 11 year age old and/or begin menstruate screen HCG ( human chorionic gonadotropin ) either urinalysis blood sample order screen pregnancy status . 6 . Patients inherit bone marrow failure syndrome ( include , limited , Fanconi anemia , ShwachmanDiamond syndrome , dyskeratosis congenital ) Down syndrome ( define either constitutional trisomy 21 constitutional mosaicism trisomy 21 ) .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>